November 1 - 2
Emory Conference Hotel
Atlanta GA

* Tentative schedule, program subject to change


Thursday, November 1

6:00 p.m. - 8:00 p.m.

Welcome Reception


Friday, November 2

7:00 a.m. - 3:00 p.m.


7:30 a.m. - 8:30 a.m.

Breakfast and Exhibit Setup

8:30 a.m. - 9:00 a.m.

Welcome Address and Opening Remarks

9:00 a.m. - 10:00 a.m.

Panel A - Vaccines: The Business of Prevention and Therapy with Modern Vaccines


Gayle D. Burstein-Teitelbaum, PhD, Senior Associate, Licensing and Business Development, The Wistar Institute

Tong Ming Fu, Senior Investigator, Merck
George Painter, CEO, Drug Innovation Ventures at Emory; Director of Emory Institute of Drug Development

Vaccines are remarkably effective in preventing viral infections. The eradication of smallpox and polio are just two examples of the widespread impact on human health. However, there is a growing list of viral pathogens against which effective vaccines are yet to be developed. Advances in small molecules therapeutic combination cocktails, offer effective treatments for HIV and Hepatitis C which have altered the course of those chronic diseases and the lives of millions of patients. The future of antiviral therapeutics is likely to depend on both approaches to treat emerging and reemerging viral pathogens. The ability to prevent and treat disease puts antivirals at the forefront of health care delivery and reducing the economic burden of disease. This session will include discussions on: 

  • New and re-emerging diseases such as Zika, Dengue, Yellow Fever and West Nile
  • Growth in Opportunistic Viral Disease due to large populations living with chronic immune deficiencies (chemotherapy and transplant patients)
  • Evolution of vaccines from RSV in infants to Pandemic Flu and Shingles in adults
  • HIV: Will there be an effective vaccine or small molecule "cure" or is PreP the best option?

10:00 a.m. - 10:15 a.m.


10:15 a.m. - 11:15 a.m.

Network Partnering

11:15 p.m. - 12:15 p.m.


12:15 p.m. - 1:45 p.m.



Maria Thacker Goethe, MPH, Executive Director, Georgia Global Health Alliance

Judith Monroe, President and CEO, Centers for Disease Control and Prevention Foundation
David A. Ross, ScD, President and CEO, The Task Force for Global Health

1:45 p.m. - 2:00 p.m.


2:00 p.m. - 3:00 p.m.

Partnering Break

3:00 p.m. - 4:00 p.m.

Panel B - Diagnostic: The Economics of Partnering

Amanda Elam, CEO, Galaxy Diagnostics
Jennifer Giordano-Coltart, PhD, JD, Partner, Intellectual Property, Chemistry and Life Sciences, Kilpatrick Townsend & Stockton LLP
Lisa Pfefferle, LabCorp
Charene Pillai, Sr. Director of Business Development, AmerisourceBergen

Diagnostics are a critical piece of healthcare delivery, yet the economics of bringing new diagnostic technologies to market has been a challenge in recent years.  Legal challenges to diagnostic patents, reimbursement challenges, and regulatory uncertainty have decelerated investing in diagnostics, even in light of exciting scientific advances.  This session will touch on: 

  • Market forces that have shaped the current diagnostics partnering environment
  • Ways some companies have/have not made it work
  • How to decide what technologies will achieve commercial success
  • How to effectively position a technology to achieve its potential for advancing human health

4:00 p.m. - 5:00 p.m.

Partnering Break

5:00 p.m.

Meeting Adjourned